玻璃体内注射贝伐单抗治疗增殖性糖尿病视网膜病变后发生的牵拉性视网膜脱离
Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy.
作者信息
Torres-Soriano Mitzy E, Reyna-Castelán Elizabeth, Hernández-Rojas Myrian, García-Aguirre Gerardo, Kon-Jara Verónica, Diaz-Rubio José L, Guerrero-Naranjo José L, Jiménez-Sierra Juan M, Quiroz-Mercado Hugo
机构信息
From the Retina Service, Asociacion Para Evitar la Ceguera, Hospital Dr. Luis Sánchez Bulnes, Coyoacan, México City, México.
出版信息
Retin Cases Brief Rep. 2009 Winter;3(1):70-3. doi: 10.1097/ICB.0b013e3181578dd8.
PURPOSE
To assess the short-term complications of a single dose of intravitreal bevacizumab in patients with proliferative diabetic retinopathy (PDR).
METHODS
Retrospective review of 343 patients with PDR who were treated with intravitreal injection of bevacizumab (2.5 mg/0.1 mL).
RESULTS
Five patients (1.45%) presented tractional retinal detachment 1 to 6 weeks (mean 3 weeks) after intravitreal injection. All cases underwent pars plana vitrectomy, removal of all epiretinal fibrovascular membranes, further endolaser panretinal photocoagulation, and silicone tamponade.
CONCLUSION
Tractional retinal detachment may occur in a short time post intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy with extensive areas of ischemia and fibrovascular proliferations, and may require prompt vitreoretinal surgery.
目的
评估单次玻璃体内注射贝伐单抗治疗增殖性糖尿病视网膜病变（PDR）患者的短期并发症。
方法
回顾性分析343例接受玻璃体内注射贝伐单抗（2.5mg/0.1mL）治疗的PDR患者。
结果
5例患者（1.45%）在玻璃体内注射后1至6周（平均3周）出现牵拉性视网膜脱离。所有病例均接受了玻璃体切除术、切除所有视网膜前纤维血管膜、进一步行全视网膜激光光凝以及硅油填充。
结论
在有广泛缺血和纤维血管增殖的增殖性糖尿病视网膜病变患者中，玻璃体内注射贝伐单抗后短时间内可能发生牵拉性视网膜脱离，可能需要及时进行玻璃体视网膜手术。
Zotero 插件